Novartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing